Dr. Do-Youn Oh
MD, PhD
Professor of Medical Oncology
corporate_fareSeoul National University Hospital, Seoul
Do-Youn Oh
MD, PhD
Prof. Do-Youn Oh is a Professor of Medical Oncology at Seoul National University Hospital (SNUH), Seoul, South Korea, and one of the world's foremost experts in biliary tract cancer. Her clinical and research work spans gastrointestinal oncology with a particular focus on biliary tract cancer, pancreatic cancer, gastric cancer, and neuroendocrine tumours.
With more than 15 years of clinical and academic experience, Prof. Oh has built an internationally recognised research profile encompassing immunotherapy, targeted therapy, antibody-drug conjugates, and FGFR-directed treatments for gastrointestinal cancers. She served as the overall lead investigator of the landmark global Phase III TOPAZ-1 trial, which enrolled 685 patients across 17 countries and demonstrated a survival benefit for durvalumab combined with gemcitabine and cisplatin in advanced biliary tract cancer — establishing a new first-line standard of care for this difficult-to-treat disease. Her Seoul National University research profile lists over 450 peer-reviewed publications and a Scopus h-index of 78. She is the recipient of the 35th Wunsch Medical Award Main Award.
Seoul National University Hospital operates an International Healthcare Center. CancerFax can coordinate medical-report review, consultation preparation, and case submission support for international patients seeking an opinion from Prof. Oh.
Why Consider Prof. Do-Youn Oh?
Prof. Oh is among the most cited gastrointestinal oncologists in Asia and the global principal investigator of the TOPAZ-1 trial that changed the first-line treatment landscape for advanced biliary tract cancer.
Areas of Specialisation
Expert in gastrointestinal oncology, biliary tract cancer, and clinical drug development
Prof. Oh's clinical and research focus spans the full spectrum of gastrointestinal malignancies, with a particular emphasis on biliary tract cancer (cholangiocarcinoma and gallbladder cancer), pancreatic cancer, gastric cancer, and neuroendocrine tumours. She is internationally recognised for pioneering immunotherapy and targeted therapy approaches in these cancers.
Biliary Tract Cancer
Advanced and recurrent biliary tract cancer including intrahepatic, extrahepatic cholangiocarcinoma, and gallbladder cancer.
- arrow_rightDurvalumab plus gemcitabine and cisplatin (first-line, TOPAZ-1 regimen)
- arrow_rightCheckpoint inhibitor therapy for eligible patients
- arrow_rightBiomarker-driven patient selection for immunotherapy
- arrow_rightFGFR2 fusion and mutation-directed therapy for cholangiocarcinoma
- arrow_rightMolecular profiling to guide FGFR inhibitor eligibility
- arrow_rightIntegration with chemotherapy backbone regimens
- arrow_rightHER2-expressing biliary tract cancer treatment approaches
- arrow_rightAntibody-drug conjugate protocols under clinical investigation
- arrow_rightTrastuzumab deruxtecan and related agents for selected cases
Pancreatic & Gastric Cancer
Systemic therapy for pancreatic cancer, gastric cancer, colorectal cancer, and neuroendocrine tumours.
- arrow_rightGemcitabine-based and FOLFIRINOX combination regimens
- arrow_rightTargeted therapy evaluation for molecularly selected pancreatic cancers
- arrow_rightParticipation in clinical trials for advanced pancreatic cancer
- arrow_rightChemotherapy and immunotherapy combinations for advanced gastric cancer
- arrow_rightFOLFOX and related regimens for colorectal and gastric cancers
- arrow_rightClinical trial access for eligible GI cancer patients
- arrow_rightSystemic management of well-differentiated and poorly differentiated neuroendocrine tumours
- arrow_rightSomatostatin analogue and targeted therapy approaches
Clinical Drug Development
Phase I–III clinical trials investigating novel systemic agents for gastrointestinal cancers.
- arrow_rightGlobal principal investigator on Phase III trials including TOPAZ-1
- arrow_rightDrug-development clinical research in GI oncology
- arrow_rightNovel agent and combination regimen evaluation
Procedures & Treatment Approaches
Systemic oncology, clinical trials, and molecular tumour profiling
Prof. Oh provides expert systemic oncology care for gastrointestinal malignancies, including chemotherapy, immunotherapy, and targeted therapy. Her clinical practice is closely integrated with her ongoing drug-development research.
Systemic Cancer Treatment
Medical OncologyChemotherapy and combination regimens for biliary tract, pancreatic, gastric, and colorectal cancers.
Immunotherapy
Targeted TherapyCheckpoint inhibitor therapy and immune-oncology combinations for GI malignancies.
Targeted & Molecular Therapy
Targeted TherapyMolecularly guided targeted therapy including FGFR inhibitors and HER2-directed agents.
Molecular Diagnostics & Staging
DiagnosisComprehensive molecular profiling to guide personalised treatment decisions.
Clinical Trials & Drug Development
Complex DiseaseAccess to Phase I–III investigational trials for gastrointestinal cancers.
Second Opinion Consultations
Second OpinionExpert independent review of pathology, molecular profiling, and treatment plans.
Research & Publications
Over 450 peer-reviewed publications and landmark Phase III trial leadership
Prof. Oh is one of the most prolific oncology researchers in Asia, with an h-index of 78 (Scopus) and over 37,000 citations. Her work has directly shaped global treatment guidelines for advanced biliary tract cancer.
Prof. Oh's active involvement in global clinical trials means eligible patients may access investigational treatments at SNUH. CancerFax can help assess eligibility and support case submission.
Education & Training
Prof. Oh completed her full medical training at Seoul National University College of Medicine, progressing from her undergraduate medical degree through to a doctoral degree in the same institution.
Clinical Experience
Prof. Oh has spent her career at Seoul National University Hospital, one of South Korea's foremost academic medical centres, where she has built an internationally recognised clinical and research programme in gastrointestinal oncology.
Languages & International
Prof. Oh conducts consultations in the following languages.
CancerFax can coordinate professional medical interpreter support for international patients requiring consultation in languages other than English or Korean.
CancerFax can coordinate professional medical interpreter support for patients consulting in other languages.
How CancerFax Helps You Access Dr. Do-Youn Oh
CancerFax is a specialist cancer patient-navigation platform. We help international patients prepare structured medical summaries, assess treatment eligibility, and connect directly with Dr. Do-Youn Oh's team — with full coordination from initial inquiry to consultation.
Medical Report Review
Free review of your pathology results, imaging, molecular profiling, and treatment history — prepared as a structured clinical summary for Dr. Do-Youn Oh's team.
Treatment Eligibility Screening
CancerFax screens your case for eligibility for treatments and clinical programmes available through Dr. Do-Youn Oh before you travel, so you arrive with a clear pathway.
Case Submission
We coordinate direct case submission to Dr. Do-Youn Oh's department, including all documentation required for clinical review and appointment scheduling.
Appointment & Consultation Coordination
CancerFax manages appointment scheduling with Dr. Do-Youn Oh's team, confirming availability and aligning timelines with your travel plans.
Travel, Visa & Logistics Support
We prepare visa invitation letters, provide hospital-proximity accommodation guidance, and coordinate airport transfers for international patients.
Follow-Up & Continuity of Care
After your consultation or treatment, CancerFax facilitates communication between Dr. Do-Youn Oh's team and your home oncologist for seamless post-treatment follow-up.
Frequently Asked Questions About Prof. Do-Youn Oh
Prof. Oh specialises in gastrointestinal malignancies, with a particular focus on biliary tract cancer (including intrahepatic and extrahepatic cholangiocarcinoma and gallbladder cancer), pancreatic cancer, gastric cancer, colorectal cancer, and neuroendocrine tumours. She is internationally recognised as a leading expert in biliary tract cancer.
Prof. Oh is a Professor of Medical Oncology at Seoul National University Hospital (SNUH) in Seoul, South Korea, one of the country's leading academic medical centres. She works within the Department of Hemato-Oncology and the Medical Oncology Center at SNUH.
TOPAZ-1 was a global Phase III clinical trial that evaluated durvalumab (an immunotherapy agent) combined with gemcitabine and cisplatin chemotherapy against chemotherapy alone as a first-line treatment for advanced or recurrent biliary tract cancer. The trial enrolled 685 patients across 17 countries and demonstrated improved overall survival with the durvalumab combination. Prof. Oh served as the overall lead investigator of the trial, and its results helped establish a new treatment standard for advanced biliary tract cancer.
Seoul National University Hospital operates a dedicated International Healthcare Center that supports international patients with appointments, language assistance, and billing guidance. CancerFax can coordinate medical-report review and consultation preparation for international patients seeking an opinion from Prof. Oh, subject to hospital availability and case acceptance.
Submit your medical reports through CancerFax using the Send Your Reports button. The CancerFax team will review your documents, prepare a structured case summary, and coordinate the next steps with SNUH on your behalf, subject to availability. For a second opinion, please include pathology reports, molecular profiling results, imaging, and your current treatment history.
Yes. FGFR-directed therapy is one of Prof. Oh's recognised areas of clinical and research expertise. For patients with intrahepatic cholangiocarcinoma and FGFR2 fusions or mutations, FGFR inhibitors may represent an important treatment option. Eligibility depends on molecular profiling results, which can be reviewed as part of a consultation or second-opinion process facilitated through CancerFax.
Yes. SNUH lists clinical trials and clinical drug-development research among Prof. Oh's specialty areas, and she has led and participated in multiple global oncology trials. Patients who may be eligible for open trials at SNUH can request an assessment through CancerFax as part of the consultation coordination process.
Connect with Do-Youn Oh Today
Share your medical reports for a free preliminary review. Our patient coordinators will help you understand your options and arrange a direct consultation.
Medical Disclaimer: Information on this page is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making any medical decisions.